The company manufactures and trades pharmaceutical products, including bulk drugs and finished formulations, primarily serving other pharmaceutical marketers and distributors.
The company operates in a highly fragmented and commoditized generic drug market with no evidence of brand power or cost advantage, as reflected by low and volatile net margins (2.8%) and mediocre ROCE (6.8%).
Management has recently pivoted toward aggressive expansion through the incorporation of new subsidiaries and a proposed merger with Chemgenix Laboratories, funded by equity dilution rather than internal cash flow.
The collapse was driven by the realization that reported earnings were a mirage, as the company failed to convert paper profits into actual cash, evidenced by a persistent negative cash conversion cycle. The aggressive expansion through the Chemgenix merger and new subsidiaries served primarily as a conduit for siphoning capital to related parties rather than building operational scale. As the revolving door of financial officers continued, internal controls crumbled, and the massive advances to entities linked to former promoters were never recovered, leaving the company insolvent and the equity worthless.
RichFakir rates Vilin Bio Med Ltd's business quality as poor — 27/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Vilin Bio Med Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Vilin Bio Med Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Vilin Bio Med Ltd's fair value is about ₹5 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →